GeneDx, based in the USA, is a leader in genetic testing with expertise in rare and ultra-rare genetic disorders. To further strengthen their molecular cytogenetics testing capabilities, they switched to a high-resolution whole-genome chromosomal microarray (CMA) for prenatal and postnatal testing.
In a series of six short videos, Thermo Fisher Scientific speaks with Dr. Jeanne Meck and Stephanie Warren from GeneDx about their journey to implement the new CMA platform utilizing a hybrid microarray consisting of both copy number and single-nucleotide polymorphism (SNP) probes.
Find out how the hybrid-SNP arrays helped GeneDx save cost, time, and resources.
Video: Preview of video series
View all episodes by filling out the form below.
Highlights of the episodes:
- DNA requirement lowered by 40%
- Reduced TAT by 9 days
- Lower inconclusive results and repeats
Accurate and reliable results on suboptimal specimen
Scientific Spotlight: All chromosomal microarrays are not created equal
Microarrays are an ideal platform for copy number variation (CNV) analysis and molecular cytogenetic research. A whole-genome microarray solution with a hybrid design including both SNPs and non-polymorphic probes provides broad coverage and high performance for detecting chromosomal aberrations with greater than 99% sensitivity. In this spotlight learn how GeneDx discovers more in a timely and cost- effective way.
Download the scientific spotlight by filling out the form below.